Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults With Severe Asthma: Results From the DESTINATION Study

被引：0

作者：

Menzies-Gow, A. ^{[1
]}

Wechsler, M. E. ^{[2
]}

Brightling, C. E. ^{[3
]}

Korn, S. ^{[4
,5
]}

Israel, E. ^{[6
]}

Bednarczyk, A. ^{[7
]}

Ponnarambil, S. ^{[8
]}

Caveney, S. ^{[9
]}

Almqvist, G. ^{[10
]}

Cook, B. ^{[11
]}

Martin, N. ^{[3
,12
]}

Kotalik, A. ^{[13
]}

Colice, G. ^{[14
]}

机构：

[1] Kings Coll London, Royal Brompton & Harefield Hosp, Sch Immunol & Microbial Sci, London, England

[2] Natl Jewish Hlth, Denver, CO USA

[3] Univ Leicester, Inst Lung Hlth, NIHR Leicester Biomed Res Ctr, Leicester, Leics, England

[4] Thoraxklin Heidelberg, Heidelberg, Germany

[5] IKF Pneumol Mainz, Mainz, Germany

[6] Harvard Med Sch, Brigham & Womens Hosp, Allergy & Immunol, Pulm & Crit Care Med, Boston, MA USA

[7] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Warsaw, Poland

[8] Astrazeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Cambridge, England

[9] Amgen Inc, Global Dev Inflammat, R&D, Thousand Oaks, CA USA

[10] AstraZeneca, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Gothenburg, Sweden

[11] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Gaithersburg, MD USA

[12] AstraZeneca, Resp & Immunol, BioPharmaceut Med, Cambridge, England

[13] AstraZeneca, Biometr, BioPharmaceut R&D, Late Stage Dev Resp & Immunol, Gaithersburg, MD USA

[14] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA

来源：

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A5987

引用

页数：2